University of Leicester
Browse

Indirect impact of the COVID-19 pandemic on hospitalisations for cardiometabolic conditions and their management: A systematic review

Download (195.06 kB)
journal contribution
posted on 2021-08-03, 16:22 authored by Samuel Seidu, Setor K Kunutsor, Xavier Cos, Kamlesh Khunti
Background
The Coronavirus disease 2019 (COVID-19) pandemic has led to a dramatic crisis in health care systems worldwide. These may have significant implications for the management of cardiometabolic diseases. We conducted a systematic review of published evidence to assess the indirect impact of the COVID-19 pandemic on hospitalisations for cardiovascular diseases and their management.

Methods
Studies that evaluated volume of hospitalisations for cardiometabolic conditions and their management with comparisons between the COVID-19 and pre-COVID periods were identified from MEDLINE, Embase and the reference list of relevant studies from January 2020 to 25 February 2021.

Results
We identified 103 observational studies, with most studies assessing hospitalisations for acute cardiovascular conditions such as acute coronary syndrome, ischemic strokes and heart failure. About 89% of studies reported a decline in hospitalisations during the pandemic compared to pre-pandemic times, with reductions ranging from 20.2 to 73%. Severe presentation, less utilization of cardiovascular procedures, and longer patient- and healthcare-related delays were common during the pandemic. Most studies reported shorter length of hospital stay during the pandemic than before the pandemic (1–8 vs 2–12 days) or no difference in length of stay. Most studies reported no change in in-hospital mortality among hospitalised patients.

Conclusion
Clinical care of patients for acute cardiovascular conditions, their management and outcomes have been adversely impacted by the COVID-19 pandemic. Patients should be educated via population-wide approaches on the need for timely medical contact and health systems should put strategies in place to provide timely care to patients at high risk.

Funding

This study was supported with a research grant from Primary Care Diabetes Europe (PCDE). PCDE as a society, has received sponsorship from Novo Nordisk, Eli Lilly and Roche Diagnostics, but the companies had no input in the study.

History

Citation

Primary Care Diabetes Volume 15, Issue 4, August 2021, Pages 653-681

Author affiliation

Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester

Version

  • AM (Accepted Manuscript)

Published in

Primary Care Diabetes

Volume

15

Issue

4

Pagination

653-681

Publisher

Elsevier

issn

1751-9918

eissn

1878-0210

Acceptance date

2021-05-23

Copyright date

2021

Available date

2022-05-28

Spatial coverage

England

Language

eng

Usage metrics

    University of Leicester Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC